Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.24 +0.68 (+1.35%)
Streaming Delayed Price Updated: 10:03 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the... 
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK ↗
In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every... 
Via Benzinga
News headline image
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations. 
Via Stocktwits
Topics Government
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal ↗
The dispute centers around Tesaro’s participation in PD-1 trials. 
Via Stocktwits
Topics Lawsuit
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January. 
Via Stocktwits
Topics Economy Government
News headline image
Hunterbrook Capital Bets Big on Achieve Life Sciences: Why a 'Toxic Tree' Could Disrupt the Multi-Billion Dollar Smoking Cessation Market
In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV)... 
Via MarketMinute
Topics Product Recall
News headline image
Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook ↗
The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026. 
Via Stocktwits
News headline image
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a... 
Via PredictStreet
News headline image
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies
Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based... 
Via PredictStreet
Topics Initial Public Offering
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition
Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax... 
Via PredictStreet
Topics Economy
News headline image
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge... 
Via MarketMinute
Topics Intellectual Property
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global... 
Via PredictStreet
Topics Earnings Initial Public Offering Intellectual Property
News headline image
GSK PLC-SPON ADR (NYSE:GSK) Shows Strong Technical Setup for Potential Breakout ↗
GSK stock shows strong technical strength and a high-quality setup, signaling a potential breakout for trend-focused investors. 
Via Chartmill
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
From GSK plc
Via Business Wire
News headline image
Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Value Stocks Stage a Comeback Bid Amidst Persistent Growth Dominance
The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
GSK PLC-SPON ADR (NYSE:GSK) Presents a High-Probability Technical Breakout Setup ↗
GSK stock shows strong technical momentum and a high-quality consolidation pattern, indicating a potential breakout opportunity for traders. 
Via Chartmill
News headline image
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗
Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries. 
Via Stocktwits
Topics ETFs
News headline image
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season. 
Via Stocktwits
Topics Economy Government
News headline image
The Best Healthcare Stock to Hold in Uncertain Times ↗
Looking for a cheap, safe healthcare stock to buy? Take two shares of GSK and call me in the morning. 
Via The Motley Fool
Topics Economy World Trade
News headline image
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs. 
Via Benzinga
News headline image
Looking Into GSK PLC's Recent Short Interest ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.